Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 571, Issue 1, Pages 39-43Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2007.06.004
Keywords
cannabinoid receptor; methamphetamine; AM251; reinstatement; self-administration; (Rat)
Categories
Funding
- NIDA NIH HHS [K02 DA000211, R01 DA004195, DA04195, DA17918, K02 DA000211-11, R01 DA004195-13, K05 DA017918] Funding Source: Medline
Ask authors/readers for more resources
Cannabinoid CB1 receptor antagonists can decrease methamphetamine self-administration. This study examined whether the CB1 receptor antagonist AM251 [N-(piperidin-1-yl)-5-(4-indophonyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide] modifies reinstatement in rats that previously self-administered methamphetamine. Rats (n = 10) self-administered methamphetamine (0.1 mg/kg/infusion) under a fixed ratio 2 schedule. Non-contingent methamphetamine (0.01-1.78 mg/kg, i.v.) yielded responding for saline (reinstatement) that was similar to responding for self-administered methamphetamine. AM251 (0.032-0.32, i.v.) did not affect methamphetamine-induced reinstatement but significantly attenuated Delta(9)-tetrahydrocannabinol (2.0 mg/kg, i.p.)-induced hypothermia. These data fail to support a role for endogenous cannabinoids or cannabinoid CB1 receptors in reinstatement and, therefore, relapse to stimulant abuse. (c) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available